A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentIncidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteersHypertension management in patients with renal cell cancer treated with anti-angiogenic agents.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewExperience with sorafenib in the treatment of advanced renal cell carcinoma.Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysisClinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.Treatment selection in metastatic renal cell carcinoma: expert consensus.Treating patients with metastatic renal carcinoma: an escape from Phase III.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumorsSudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity
P2860
Q22305863-65C50EA5-1245-4540-AD99-FC672A68BD45Q26782585-D34D587E-6766-44C1-91D2-E11386CCB71BQ35198387-B42889AF-3E01-439E-8ABD-7ADD893F1680Q35677270-B90E9CD3-6478-479D-9EC9-CB8D27C73E0AQ35914782-E8811489-328F-4171-80D4-964CF9EC4087Q36136849-F3150C57-3D72-480A-9732-3CB77902529BQ36270115-F7F13F85-BB80-4D73-9C64-DE8CCBE0A369Q36379345-1620CC9A-B816-4362-8DE8-94A9B9DA3867Q36594084-3470F97D-A70F-41F1-9921-5DBE777E6A97Q37283736-3DB92E7C-A285-424F-9015-A67DEBC9CE57Q37507871-6C0A108B-980A-48EE-84ED-CCF4712C310DQ37537655-1813B20C-8856-42C1-8032-50DB672785CEQ37999655-AA6E8950-A443-4A39-9BD0-C7EB06FD4DA1Q38030592-820B4E88-3F28-4B7F-94FD-C432B198A06CQ38099040-57ABF508-E981-4C11-BB30-52C6E7C2822BQ38110320-F3B3646E-B820-40FA-B84A-1DCE9BABCD56Q38155199-BADD37AC-29F8-4BF1-A6EE-A5DAB52D0D0CQ38190857-B5DC1C6C-B52A-45A5-917C-7EFBDC37FD74Q40770030-DE25465D-ED82-4589-88D0-4D956699A04EQ41816476-56BA24F6-244A-4FE0-BD1D-3ACD3CECAEF1Q42136590-E9AF6A81-377D-4CDD-B208-5B4804A577AEQ42703704-F0B74145-EC13-457E-BB37-A89F0345CAC7Q43657215-82D25CBC-2BCE-4CEC-A423-A162A451697EQ44591315-3AB9E095-01E6-4599-852D-12035AC76A1AQ47727992-60F679E4-049E-401B-B0C9-062F4F205B67Q47969048-53CB37F7-1644-48B2-B54A-7E534D1589E6Q49244147-4BB3982F-7ED1-41A4-B06F-A7610FF2F92AQ52863110-FC99B06E-41C8-4E20-B1E8-AAE0312879D4Q54196218-09B5C89B-A2C4-4EBF-90FB-D9816DB11F3AQ54365531-E02C85A3-C219-48FA-977C-42BCCEB3E6D8Q58548679-AFFC00B7-A00C-4019-AF94-7B5E941274FD
P2860
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A phase I open-label study eva ...... patients with advanced cancer.
@ast
A phase I open-label study eva ...... patients with advanced cancer.
@en
A phase I open-label study eva ...... patients with advanced cancer.
@nl
type
label
A phase I open-label study eva ...... patients with advanced cancer.
@ast
A phase I open-label study eva ...... patients with advanced cancer.
@en
A phase I open-label study eva ...... patients with advanced cancer.
@nl
prefLabel
A phase I open-label study eva ...... patients with advanced cancer.
@ast
A phase I open-label study eva ...... patients with advanced cancer.
@en
A phase I open-label study eva ...... patients with advanced cancer.
@nl
P2093
P2860
P1476
A phase I open-label study eva ...... patients with advanced cancer.
@en
P2093
Alain C Mita
Anthony W Tolcher
Arthur Mazzu
Frank Cihon
Geoffrey I Shapiro
Leonard J Appleman
Pavur R Sundaresan
P2860
P2888
P304
P356
10.1007/S00280-010-1372-3
P577
2010-06-03T00:00:00Z
P5875
P6179
1032910148